247 related articles for article (PubMed ID: 15631538)
1. Eplerenone: a review of its use in essential hypertension.
Croom KF; Perry CM
Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
4. Eplerenone--a novel selective aldosterone blocker.
Zillich AJ; Carter BL
Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
[TBL] [Abstract][Full Text] [Related]
5. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Barnes BJ; Howard PA
Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
[TBL] [Abstract][Full Text] [Related]
9. Hypertension, angiotensin II, aldosterone, and race.
Ben-Yehuda O
J Am Coll Cardiol; 2003 Apr; 41(7):1156-8. PubMed ID: 12679216
[No Abstract] [Full Text] [Related]
10. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
[TBL] [Abstract][Full Text] [Related]
11. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
[TBL] [Abstract][Full Text] [Related]
13. Eplerenone: a selective aldosterone blocker.
Stier CT
Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
[TBL] [Abstract][Full Text] [Related]
14. [The revived interest in aldosterone antagonists].
Waeber B
Rev Med Suisse; 2006 Sep; 2(78):2055-8. PubMed ID: 17019841
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
Davis KL; Nappi JM
Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
[TBL] [Abstract][Full Text] [Related]
16. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
17. Treatment considerations with aldosterone receptor antagonists.
Sica DA; Flack JM
J Clin Hypertens (Greenwich); 2011 Jan; 13(1):65-9. PubMed ID: 21214724
[No Abstract] [Full Text] [Related]
18. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.
Danjuma MI; Mukherjee I; Makaronidis J; Osula S
Curr Hypertens Rep; 2014 Feb; 16(2):414. PubMed ID: 24407447
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
Sato A
Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
[TBL] [Abstract][Full Text] [Related]
20. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
